OptimizeRx Corp. Fundamental Analysis (NASDAQ: OPRX)
OptimizeRx Corp. Fundamental Analysis (NASDAQ: OPRX)
OptimizeRx Corp. (NASDAQ: OPRX) shows weak financial fundamentals with a PE ratio of 36.12, profit margin of 4.66%, and ROE of 3.60%. The company generates $0.1B in annual revenue with strong year-over-year growth of 18.78%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 55.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze OPRX's fundamental strength across five key dimensions:
Efficiency Score
WeakOPRX struggles to generate sufficient returns from assets.
Valuation Score
ModerateOPRX shows balanced valuation metrics.
Growth Score
ModerateOPRX shows steady but slowing expansion.
Financial Health Score
ExcellentOPRX maintains a strong and stable balance sheet.
Profitability Score
WeakOPRX struggles to sustain strong margins.
Key Financial Metrics
Is OPRX Expensive or Cheap?
P/E Ratio
OPRX trades at 36.12 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, OPRX's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values OptimizeRx Corp. at 1.26 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.88 times EBITDA. This signals the market has high growth expectations.
How Well Does OPRX Make Money?
Net Profit Margin
For every $100 in sales, OptimizeRx Corp. keeps $4.66 as profit after all expenses.
Operating Margin
Core operations generate 11.45 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.60 in profit for every $100 of shareholder equity.
ROA
OptimizeRx Corp. generates $2.80 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
OptimizeRx Corp. produces operating cash flow of $18.41M, showing steady but balanced cash generation.
Free Cash Flow
OptimizeRx Corp. generates strong free cash flow of $18.34M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.98 in free cash annually.
FCF Yield
OPRX converts 11.03% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
36.12
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.001
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.26
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.67
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.15
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.58
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How OPRX Stacks Against Its Sector Peers
| Metric | OPRX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 36.12 | 31.50 | Worse (Expensive) |
| ROE | 3.60% | 422.00% | Weak |
| Net Margin | 4.66% | 19867.00% | Weak |
| Debt/Equity | 0.15 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 5.58 | 5.56 | Strong Liquidity |
| ROA | 2.80% | 1571.00% | Weak |
OPRX outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews OptimizeRx Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
101.89%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
285.81%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
337.00%
Industry Style: Defensive, Growth, Innovation
High Growth